India to Chile: Acetaminophen Export Trade Route

The Instituto de Salud Pública de Chile (ISP) is the regulatory authority overseeing the registration and importation of pharmaceutical products, including Acetaminophen formulations. To import these products into Chile, the following approvals and registrations are necessary:

• Product Registration: All pharmaceutical products must be registered with the ISP before importation. The registration process involves submitting a comprehensive dossier in the Common Technical Document (CTD) format, which includes detailed information on the product's quality, safety, and efficacy.

• Dossier Submission: The CTD dossier should encompass modules covering administrative information, quality data, non-clinical study reports, and clinical study reports.

• Approval Timelines: The registration process typically takes between 6 to 18 months, depending on the completeness and accuracy of the submitted documentation.

• Registration Fees: As of the latest available data, the registration fee is approximately US$2,300.

• GMP Inspection Requirements: The ISP mandates that manufacturing facilities comply with Good Manufacturing Practices (GMP). While the ISP may conduct inspections, it often recognizes GMP certifications issued by other stringent regulatory authorities, such as the World Health Organization (WHO).

Indian manufacturers exporting Acetaminophen formulations to Chile must adhere to the following quality and GMP standards:

• GMP Certification: Manufacturers must possess a valid GMP certificate, preferably issued by the WHO or recognized national authorities. This certification ensures that the manufacturing processes meet international quality standards.

• Certificate of Pharmaceutical Product (COPP): A COPP, issued by the Central Drugs Standard Control Organization (CDSCO) in India, is required to certify that the pharmaceutical product is authorized for sale in India and complies with GMP standards.

• Quality Control Documentation: Each batch of the product must be accompanied by a Certificate of Analysis (CoA) from an accredited laboratory, verifying the product's quality, purity, and potency.

• Compliance with Chilean Regulations: Manufacturers must ensure that their products meet the specific requirements set forth by the ISP, including stability data appropriate for Chile's climatic conditions (Zone IVb: hot and humid).

As of March 2026, there have been no publicly reported regulatory actions by the ISP against Indian pharmaceutical companies exporting to Chile. However, manufacturers are advised to stay updated on regulatory requirements to maintain compliance.

Several regulatory changes and developments have occurred in the past 18 months affecting Indian pharmaceutical exports to Chile:

• Revised GMP Regulations in India: On January 6, 2024, India's Ministry of Health published revised GMP regulations to align with global standards, particularly those of the WHO. These revisions aim to enhance the quality of pharmaceutical products and may impact Indian exporters by necessitating updates to their manufacturing practices.

• Implementation of Bioequivalence Certification in Chile: The ISP has been progressively implementing bioequivalence certification requirements for certain pharmaceutical products. While the list of active ingredients requiring such certification has been expanding since 2011, exporters should verify whether Acetaminophen formulations are subject to these requirements to ensure compliance.

Staying informed about these regulatory developments is crucial for Indian exporters to ensure uninterrupted access to the Chilean market.

As of 2024, the global acetaminophen market was valued at approximately USD 10.93 billion, with projections indicating growth to USD 17.62 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.45% during the 2024-2032 period. While specific data for Chile is limited, the country's demand for acetaminophen formulations is influenced by several factors:

• Healthcare Spending: Chile's healthcare expenditure has been steadily increasing, enhancing access to medications, including over-the-counter analgesics like acetaminophen.

• Aging Population: The proportion of individuals aged 65 and over in Chile is rising, leading to a higher prevalence of chronic pain conditions that often require management with analgesics.

• Universal Health Coverage: Chile's commitment to universal health coverage ensures that a broad segment of the population has access to essential medicines, including acetaminophen formulations.

Regarding supply, Chile imports finished pharmaceutical formulations containing acetaminophen from various countries, including India. Domestic manufacturing capabilities exist but are complemented by imports to meet the full demand.

Pharmaceutical imports into Chile under HS code 30049069 are subject to a 6% MFN import duty. Additionally, a Value Added Tax (VAT) of 19% is applied to the sum of the Cost, Insurance, and Freight (CIF) value plus the import duty. The India-Chile Preferential Trade Agreement (PTA) provides for reduced tariffs on certain products, including pharmaceuticals, which may lower the import duty rate for eligible acetaminophen formulations imported from India. There are no specific anti-dumping duties imposed on acetaminophen imports into Chile.

India is a notable supplier of finished pharmaceutical formulations containing acetaminophen to Chile, accounting for approximately 0.5% of India's total acetaminophen formulation exports, valued at $1.2 million USD across 25 shipments. Major Indian exporters include Granules India Limited and Baroque Pharmaceuticals Pvt Ltd. Key Chilean importers are Laboratorio Chile SA and OPKO Chile S.A.

Other significant suppliers to the Chilean market include manufacturers from the European Union and China. India's competitive pricing, coupled with the benefits of the India-Chile PTA, positions it favorably against these competitors. The combination of cost-effectiveness and adherence to international quality standards enhances India's appeal as a supplier of acetaminophen formulations to Chile.

India has established itself as a global leader in the production of generic pharmaceuticals, including formulations containing acetaminophen. As of 2024, the country operates 752 FDA-approved manufacturing facilities, surpassing the United States in this regard. Additionally, India boasts 2,050 WHO-GMP certified plants, reflecting its commitment to maintaining high manufacturing standards.

The cost structure of Indian pharmaceutical manufacturing is notably competitive, with production costs approximately 30% to 35% lower than those in the U.S. and Europe. This advantage is primarily due to lower labor expenses and the adoption of advanced digital technologies.

Indian manufacturers have also demonstrated a strong compliance record, with a 50% reduction in FDA Official Action Indicated (OAI) outcomes over the past decade. This improvement underscores the industry's dedication to quality and regulatory adherence.

In the third quarter of 2025, the price of paracetamol (acetaminophen) in India was approximately $2,911 per metric ton, which is lower than the prices in China ($3,415/MT) and Germany ($3,496/MT). This pricing advantage extends to finished dosage forms, making Indian formulations more cost-effective for international buyers.

Quality perception and regulatory acceptance of Indian pharmaceutical products are strong, with the country operating the largest number of FDA-approved generic medicine facilities globally. This extensive regulatory approval facilitates smoother market entry and acceptance in various countries, including Chile.

Supply reliability is another critical factor. Indian manufacturers have invested significantly in infrastructure and operations, leading to a 40% increase in on-time-in-full delivery rates between 2014 and 2023. This improvement surpasses the global average of 1%, indicating a robust and dependable supply chain.

The India-Chile supply chain for acetaminophen formulations has demonstrated reliability, supported by India's substantial manufacturing capacity. The country's pharmaceutical industry has seen a 24% increase in labor productivity from 2014 to 2023, enhancing overall production efficiency.

Packaging and cold chain capabilities are well-developed, ensuring the integrity of pharmaceutical products during transit. There have been no significant supply disruptions reported in recent years, reflecting the stability of the supply chain.

Indian manufacturers maintain a strong regulatory compliance track record, with a notable reduction in FDA OAI outcomes over the past decade. This compliance ensures consistent product quality and adherence to international standards.

While specific capacity constraints or expansion plans among top Indian formulation manufacturers are not detailed, the overall industry trend indicates ongoing investments in infrastructure and operations to meet global demand.

For Chilean buyers sourcing acetaminophen formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Familiarize yourself with common payment terms in India-Chile pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to facilitate smooth transactions.

• Supplier Qualification Process: Implement a thorough qualification process, including audits and compliance checks, to ensure suppliers meet regulatory standards and quality expectations.

• Regulatory Compliance: Stay updated on both Indian and Chilean regulatory requirements to ensure seamless importation and market entry of the formulations.

By adopting these strategies, Chilean buyers can effectively source high-quality, cost-effective acetaminophen formulations from India, leveraging the country's manufacturing advantages and robust supply chain.

Before initiating procurement of acetaminophen formulations from Indian suppliers, Chilean buyers should adhere to the following pre-qualification steps:

Prior to finalizing procurement, Chilean buyers should request the following documents from Indian acetaminophen formulation suppliers:

When evaluating Indian suppliers of acetaminophen formulations, Chilean buyers should be vigilant for the following warning signs:

Conducting thorough audits and establishing ongoing monitoring mechanisms are crucial for ensuring the quality and compliance of acetaminophen formulations sourced from Indian manufacturers:

Cost Estimates and Timeline:

• Audit Visits to India:
• Cost: Approximately $5,000 to $10,000 USD per audit, covering travel, accommodation, and professional fees.
• Timeline: Planning and execution typically require 4 to 6 weeks, including scheduling, travel arrangements, on-site inspection, and reporting.

By adhering to these guidelines, Chilean buyers can ensure the quality, safety, and regulatory compliance of acetaminophen formulations procured from Indian manufacturers.